The gold-standard therapy for the treatment of wet AMD is represented by intravitreal injections of anti-VEGF drugs, which are able to limit VEGF function, including Ranibizumab®, Brolucizumab®, and Aflibercept®. The gene discussed is VEGFA; the disease is wet macular degeneration.